Forte Biosciences 将来の成長

NasdaqCM:FBRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	N/A	N/A	N/A	1
12/31/2025	N/A	N/A	N/A	N/A	2
12/31/2024	N/A	N/A	N/A	N/A	2
9/30/2024	N/A	-34	-30	-30	N/A
6/30/2024	N/A	-36	-31	-31	N/A
3/31/2024	N/A	-32	-30	-30	N/A
12/31/2023	N/A	-31	-29	-29	N/A
9/30/2023	N/A	-30	-23	-23	N/A
6/30/2023	N/A	-24	-16	-16	N/A
3/31/2023	N/A	-18	-11	-11	N/A
12/31/2022	N/A	-14	-8	-8	N/A
9/30/2022	N/A	-12	-9	-9	N/A
6/30/2022	N/A	-17	-12	-12	N/A
3/31/2022	N/A	-19	-15	-15	N/A
12/31/2021	N/A	-22	-17	-17	N/A
9/30/2021	N/A	-23	-17	-17	N/A
6/30/2021	N/A	-20	-20	-20	N/A
3/31/2021	N/A	-49	-20	-20	N/A
12/31/2020	N/A	-46	-18	-18	N/A
9/30/2020	N/A	-43	-15	-15	N/A
6/30/2020	N/A	-39	-8	-8	N/A
3/31/2020	N/A	-5	-5	-5	N/A
12/31/2019	N/A	-4	-3	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: FBRXの予測収益成長が貯蓄率 ( 2.6% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: FBRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: FBRXの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: FBRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: FBRX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: FBRXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Forte Biosciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 25% to US$4.38

Price target increased to US$103

Forecast to breakeven in 2025

Recent updates

Forte Biosciences, Inc. announced that it expects to receive $53 million in funding from OrbiMed Advisors LLC, Janus Henderson Group plc, Tybourne Capital Management Limited, Ikarian Capital, LLC, BVF Partners L.P., Fred Alger Management, LLC

High number of new directors

High number of new directors

New major risk - Market cap size

New major risk - Share price stability

Price target increased by 25% to US$4.38

Forte Biosciences, Inc., Annual General Meeting, Aug 20, 2024

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

New minor risk - Share price stability

New major risk - Financial position

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New major risk - Financial position

High number of new directors

Forte Biosciences Receives Non-Compliance Letter from Nasdaq

Camac Partners Shares Key Facts that Reinforce the Need for Urgent Change in Forte Biosciences’s Boardroom

Forte Biosciences, Inc., Annual General Meeting, Sep 19, 2023

New major risk - Shareholder dilution

Forte Biosciences, Inc appoints David Gryska to the Board of Directors

CEO & Chairman recently bought US$105k worth of stock

High number of new and inexperienced directors

Forte Biosciences, Inc. Announces Dr. Scott Brun to Its Board of Directors

Cable Car Capital Expects Response of Forte Biosciences for its Concerns

Cable Car Capital Waiting for the Response of Forte Biosciences

Cable Car Capital Sends Letter to the Board of Forte Biosciences

Large Forte Biosciences shareholder scolds company board of directors

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Forte Biosciences large shareholders make demands for company's future

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

BML Capital Management Sends an Email to Chairman & CEO of Forte Biosciences

Forte Biosciences, Inc. Appoints Stephen K. Doberstein to its Board

Forte Biosciences, Inc., Annual General Meeting, Jun 01, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

High number of new and inexperienced directors

President recently sold US$4.3m worth of stock

Price target increased to US$103

Director Thomas Darcy has left the company

Forte Biosciences files for $300M mixed shelf offering

Forecast to breakeven in 2025

Forte Biosciences, Inc. Expects to Report the Topline Results from That Trial in the Third Quarter of 2021

Forte Biosciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

New 90-day low: US$30.76

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2000 Dynamic Index

New 90-day low: US$33.73

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Forte Biosciences readies equity offering

Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis

Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults with Atopic Dermatitis

New 90-day high: US$50.69

Forte Biosciences, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell Small Cap Completeness Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 3000 Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2500 Growth Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘